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The PlA1/A2 Polymorphism of Glycoprotein IIIa as a Risk
Factor for Myocardial Infarction: A Meta-Analysis
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Department of Clinical Pharmacology, Cardiovascular Division, British Heart Foundation Centre of Research Excellence, King’s College London, London, United Kingdom
Abstract
Background: The PlA2 polymorphism of glycoprotein IIIa (GPIIIa) has been previously identified as being associated with
myocardial infarction (MI), but whether this represents a true association is entirely unclear due to differences in findings
from different studies. We performed a meta-analysis to evaluate whether this polymorphism is a risk factor for MI.
Methods: Electronic databases (MEDLINE and EMBASE) were searched for all articles evaluating genetic polymorphisms of
GPIIIa. For studies where acute coronary events were recorded in association with genetic analysis, pooled odds ratios (ORs)
were calculated using fixed-effects and random-effects models. The primary outcome measure was MI, and a secondary
analysis was also performed for acute coronary syndromes (ACS) more generally.
Findings: 57 studies were eligible for statistical analysis and included 17,911 cases and 24,584 controls. Carriage of the PlA2
allele was significantly associated with MI (n= 40,692; OR 1.077, 95% CI 1.024–1.132; p = 0.004) but with significant
publication bias (p = 0.040). The degree of association with MI increased with decreasing age of subjects (#45 years old:
n= 9,547; OR 1.205, 95% CI 1.067–1.360; p = 0.003) and with adjustment of data for conventional cardiovascular risk factors
(n= 12,001; OR 1.240, 95% CI 1.117–1.376; p,0.001). There was a low probability of publication bias for these subgroup
analyses (all p,0.05).
Conclusions: The presence of significant publication bias makes it unclear whether the association between carriage of the
PlA2 allele and MI is true for the total population studied. However for younger subjects, the relative absence of
conventional cardiovascular risk factors results in a significant association between carriage of the PlA2 allele and MI.
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Introduction
The fibrinogen receptor is the most abundant integrin on the
platelet surface [1], and through binding a combination of
fibrinogen, von Willebrand factor and fibronectin, its main
function is to terminate haemorrhage following vascular injury.
Despite this important physiological function, it also plays a
pathological role when stimulated excessively or inappropriately,
and is a principal mediator of acute coronary thrombosis [2].
The glycoprotein IIIa (GPIIIa) subunit of the fibrinogen
receptor has a number of stable allelic variants resulting from
single amino acid substitutions [3], of which the PlA1/A2 diallelic
antigen system (involving a leucine-proline polymorphism at
position 33, which alters the protein conformation and spatial
orientation of the ligand-binding region) has been associated with
an increased prevalence of cardiovascular disease. In 1996, Weiss
et al reported an association between carriage of the PlA2 allele
and cardiovascular disease, with the association most marked in
subjects with unstable angina or myocardial infarction (MI) under
60 years of age (Odds ratio (OR) 6.2, 95% confidence interval (CI)
1.8–22.4; p = 0.002) [4]. The subsequent literature has demon-
strated marked inter-study variation in the level – and indeed
presence – of such an association, which in part reflects generally
underpowered investigations of an allele with a frequency in
Caucasian populations of approximately 15 per 100 [5], falling to
1 per 100 in Oriental populations [6].
A number of meta-analyses have investigated the association
between carriage of the PlA2 allele and cardiovascular disease. In
2001 Di Castelnuovo et al identified a significant association
between PlA2 carriage and coronary artery disease (n=17,049;
OR 1.10, 95% CI 1.03–1.18), but found no significant association
with MI (n=11,628; OR 1.09, 95% CI 0.97–1.22) [7]. A
subsequent meta-analysis also found no association with either
MI (n=30,630; per-allele RR 1.02, 95% CI 0.96–1.07) or
coronary stenosis (n=12,741; per-allele RR 1.04, 95% CI 0.97–
1.13) [8].
The identification of a contribution by a single gene polymor-
phism to a multifactorial, polygenic pathological process is
challenging and requires a very large sample size [9]. Here we
present the largest meta-analysis to date, involving 42,495 subjects,
to address the question of whether carriage of the PlA2
polymorphism is an independent risk factor for acute coronary
events.
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Methods
Search strategy and selection criteria
Electronic databases (MEDLINE and EMBASE) were searched
without language restriction up until 1st April 2013 for all articles
evaluating genetic polymorphisms in the platelet GPIIIa receptor.
The Medical Subject Headings terms used for the primary search
related to genetics (e.g. ‘gene’, ‘polymorphism’, ‘mutation’ and
‘genotype’) in combination with glycoprotein IIIa (e.g. ‘glycopro-
tein IIIa’, ‘GP IIIa’ and ‘integrin beta 3’). Following removal of
duplicates, a total of 2,288 articles were identified in the primary
search. To further encompass all relevant literature, a secondary
search of the references from reviews and included studies was
performed.
All articles that investigated the association between carriage of
the PlA2 polymorphism and acute coronary syndromes (ACS)
were considered potentially eligible for inclusion and, based on
analysis of title and abstract, 114 potentially suitable articles were
identified. For inclusion into the meta-analysis, studies must have
reported the distribution of the PlA1/A2 genotype in relation to
the prevalence of a coronary event, either as raw data or
calculated ORs. Both case-control and cohort studies were
considered, with familial-based studies and studies without an
English translation excluded.
A number of studies were not suitable for inclusion based on the
following reasons: 12 studies were unavailable in English [10–21],
three studies were familial-based [22–24], seven studies reported
data that duplicated or overlapped with larger studies that were
eligible for inclusion [25–31], 26 studies did not contain suitable
outcome data [32–57], and in 11 studies all subjects had a
coronary event and so there was no control population [58–68].
Following the addition of three studies identified in the secondary
search [69–71], a total of 57 studies met the inclusion criteria for
statistical analysis (Figure 1).
Data extraction
Data were extracted from each study according to a predefined
protocol: study design, number of cases/controls, geographic
location and/or ethnicity, sex and clinical outcome. The primary
outcome measure was MI with a secondary outcome being ACS
more generally. For the secondary outcome measure, data on the
incidence of ACS were included preferentially where MI incidence
was also reported.
Ethnic group was recorded where explicitly stated within a
study. Where genotype information was reported for .1 sub-
population as defined by geographic region or ethnic origin, each
sub-population was considered separately in the analyses [9]. This
was the case for studies by Herrmann et al and Kekomaki et al
[72,73].
Where data adjusted for age, gender, ethnicity and cardiovas-
cular risk factors were available, these were analysed in preference
to raw data. Similarly, in studies which had more than one control
group, subjects with coronary artery disease were used in
preference to healthy subjects as controls.
Statistical analysis
Data were analysed using Comprehensive Meta-analysis soft-
ware, version 2 (Biostat, USA). Pooled ORs were calculated using
fixed- and random-effects models, along with the 95% CI to
measure the strength of association. Fixed-effects summary ORs
were calculated using the Mantel-Haenszel method [74], and the
DerSimonian method was used to calculate random-effects
summary Ors [75]. For data where more than one outcome was
reported, combined effects were calculated as necessary [76].
Pooled ORs presented in the results were calculated using the
fixed-effects model unless otherwise stated.
Tests for heterogeneity were performed for each meta-analysis,
with significance set at p,0.05 [77]. I2 was also calculated for each
analysis, where $50% may represent substantial heterogeneity
[78]. For assessment of publication bias, we utilised a funnel plot
and Egger’s regression asymmetry test [79]. In addition, the effect
of individual studies on the summary OR was evaluated by re-
estimating and plotting the summary OR in the absence of each
study.
Results
We identified 53 studies with the endpoint of myocardial
infarction, comprising a total of 16,863 cases and 23,829 controls.
Pooled OR for the association of carriage of the PlA2 allele (PlA1/
A2+PlA2/A2 versus PlA1/A1 genotype) with MI was significant at
1.077 (95% CI 1.024–1.132; p = 0.004) (Figure 2) [70–73,80–128].
Significant heterogeneity was observed (I2 = 57.9%; p,0.001), and
analysis using the random-effects model increased the degree of
association (OR 1.132, 95% CI 1.039–1.232; p = 0.004). The
addition of three further studies to assess the association with ACS
more generally yielded an OR of 1.074 (n=42,426; 95% CI
1.023–1.127; p = 0.004) (Table 1) [4,69,129].
Analysis of the association between carriage of the PlA2 allele
and MI using data adjusted for age, sex, ethnicity and
cardiovascular risk factors demonstrated an increased level of
association (n=12,001; OR 1.240, 95% CI 1.117–1.376; p,
0.001) [87,88,96,97,101,109,110,112,119–121,125,127]. Further
subgroup analysis based on comparison of the PlA1/A1 versus
PlA2/A2 genotype failed to show a significant association
(n=23,836; OR 1.023, 95% CI 0.877–1.192; p = 0.774)
[70–72,81,82,86–91,95,98–100,102–104,106–108,111–114,116,117,
120,122,124,128] (Figure 3); however, within this analysis, the
number of subjects with the PlA2/A2 genotype was small, consisting
of 333 cases and 1,504 controls.
Figure 1. Summary of strategy used to identify studies suitable
for analysis.
doi:10.1371/journal.pone.0101518.g001
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Figure 2. Analysis of the association between carriage of the PlA2 allele and myocardial infarction. Analysis is of the PlA1/A1 versus
PlA1/A2+PlA2/A2 genotype.
doi:10.1371/journal.pone.0101518.g002
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Subgroup analyses based on subject demographics
Data were available to calculate pooled ORs based on subject
ethnicity, sex and age (Table 2). Analysis based on ethnicity was
limited to Caucasians as the majority of studies did not explicitly
state the ethnicity of participants. A non-significant pooled OR for
the association of PlA2 carriage with MI was observed for the 11
available studies (n=10,585; OR 1.050, 95% CI 0.962–1.146;
p = 0.272) [71,81,88,95–97,103,109,112,127,128].
The association between PlA2 carriage and MI in male subjects
was observed to be consistent with the primary analysis (n=8,686;
OR 1.145, 95% CI 1.018–1.288; p= 0.024) [72,84–
86,97,99,114,115,120,123,127]. Only two studies provided data
for female subjects, resulting in no significant association observed
in these (n=5,237; OR 0.961, 95% CI 0.703–1.312; p= 0.801)
[86,120].
Subgroup analyses based on subject age at first MI demon-
strated an increased level of association with decreasing age
(Figure 4). For subjects #45 years old, carriage of the PlA2 allele
produced a pooled OR for MI of 1.205 (n=9,547; 95% CI 1.067–
1.360; p = 0.003) with significant heterogeneity (I2 = 70.3%, p,
0.001), and analysis using the random-effects model again
increased the level of association (OR 1.356, 95% CI 1.044–
1.762; p = 0.022) [72,82,84,86,91,97,107,116,121–123]. Signifi-
cant heterogeneity and an increased level of association as
compared with the total population were also observed using the
random-effects model for the #55 and #65 year-old subgroups.
In 15 of the studies identified, the recorded cardiovascular event
was a ‘first event’ for the participant. Analysis of these studies
revealed an association between carriage of the PlA2 allele and MI
that was stronger than that seen in the primary analysis
(n=18,349; OR 1.131, 95% CI 1.036–1.234; p= 0.006)
[82,84,86,87,90,101,104,107,111,117,119–122,124,125].
Subgroup analyses based on study characteristics
As described within the Methods, adjusted data were analysed
in preference to raw data wherever possible in order to distinguish
the true effect of the PlA2 allele against a background of
conventional cardiovascular risk factors. Similarly, in studies
where more than one control population was included, the group
with coronary artery disease was selected in preference to healthy
subjects as the control group. These data are all displayed in
Table 3. Subgroup analysis of crude data using only healthy
controls found an increased association between PlA2 carriage and
MI compared to the primary analysis (n=29,907; OR 1.098, 95%
CI 1.033–1.166; p = 0.003) [71–73,81–84,86–91,96,98,99,102–
104,107,108,110–113,115–117,119–125,127,128], whereas analy-
sis of raw data using controls with known coronary artery disease
found no significant association (n=11,819; 95% CI 0.941–1.114;
p = 0.583) (Figure 5) [80,85,87,88,92–94,96,100,105,106,108,
114,118,126–128].
Study design was found to influence the degree of association.
Cohort studies did not demonstrate an association between
carriage of the PlA2 allele and MI (n=19,032; OR 0.996, 95%
CI 0.917–1.082; p= 0.926) [80,85,86,92–95,97,100,105,106,
109,112,114,118,125,126], whereas case-control studies did
(n=21,660; OR 1.126, 95% CI 1.057–1.198; p,0.001) (Figure 6)
[70–73,81–84,87–91,96,98,99,101–104,107,108,110,111,113,115–
117,119–124,127,128]. Studies with ,250 cases showed a signif-
icant association (n=10,145; OR 1.240, 95% CI 1.139–1.350;
p= 0.006) [70,72,73,80–83,85,88–94,97,98,102,103,105,108,110,
111,113–116,118–127,130], whereas studies with $250 cases did
not (n=30,547; OR 0.999, 95% CI 0.935–1.084; p= 0.864)
[71,72,84,86,87,95,96,99–101,104,106,107,109,112,117,128].
Eleven out of 17 studies with $250 cases were case-control studies
[71,72,84,87,99,101,104,107,117,120,128].
Publication bias
Publication bias was assessed by plotting funnel plots and
calculation of Egger’s regression intercept. The funnel plot for the
primary analysis was asymmetric with a significant Egger’s
regression intercept (p = 0.040), suggesting the likelihood of
publication bias skewed towards studies that favour an association
between carriage of the PlA2 allele and MI (Figure 7). This bias
was independent of study size (,250 cases, p = 0.264; $250 cases,
p = 0. 088), but dependent on study design (case-control studies,
p = 0.021; cohort studies, p = 0.570). Further analysis of case-
Table 1. Association between carriage of the PlA2 polymorphism and acute coronary events.
Number of studies
Number of cases/
controls
Pooled OR*
(95% CI)
Association
(p value) I2 (%)
Primary analysis:
MI 53 16,863/23,829 1.077 0.004 57.9
[70–73,80–128] (1.024–1.132)
Secondary and subgroup analyses:
ACS 56 17,887/24,539 1.074 0.004 59.3
[4,69–73,80–129] (1.023–1.127)
MI (adjusted data) 13 6,188/5,813 1.240 ,0.001 47.6
[87,88,96,97,101,109,110,112,119–121,125,127] (1.117–1.376)
PlA1/A1 vs PlA2/A2 31 7,245/16,591 1.023 0.287 40.8
[70–72,81,82,86–91,95,98–100,102–104,106–
108,111–114,116,117,120,122,124,128]
(0.877–1.192)
*OR (odds ratio) calculated using fixed-effects model for carriage of the PlA2 allele vs PlA1 homozygous subjects.
[MI = myocardial infarction; ACS = acute coronary syndrome].
doi:10.1371/journal.pone.0101518.t001
The PlA2 Allele and Risk of MI
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control studies suggested that this bias was not associated with
study size (,250 cases, p = 0.157; $250 cases, p = 0.066).Signif-
icant bias was not present for the subgroup analyses based on age
(#65, p = 0.161; #55, p = 0.191; #45, p= 0.192).
Discussion
The data presented here appears to demonstrate an increased
risk of MI in carriers of the PA2 allele, with an association that
becomes stronger as age decreases. Significant publication bias
identified in the primary analysis makes it unclear whether the
association is true for the totality of the population studied. This
bias is primarily driven by case-control studies and surprisingly
independent of study size given that smaller studies are generally
more prone to this effect. The presence of bias is consistent with
the general findings of the two previous meta-analyses [7,8].
However despite these concerns, there remains a clear age effect
with the association between carriage of the PlA2 allele and MI
most evident for younger age cohorts.
The observed age-skewed risk profile may be explained by a
relative (rather than absolute) decrease in the influence of genetic
factors with age, given that the prevalence of conventional
cardiovascular risk factors increases with age [131]. This
hypothesis is supported by the increased association between
carriage of the PlA2 allele and MI observed in the subgroup
analysis using data adjusted for these risk factors. Similarly,
subgroup analysis using unadjusted data and controls with
coronary artery disease resulted in no significant association seen,
and this is likely to be explained again by the dilution effect caused
by the coexistence of conventional risk factors.
Aetiology of increased risk
It is unclear as to the mechanism by which carriage of PlA2
predisposes to increased cardiovascular morbidity and mortality.
The aetiology of cardiovascular risk is not monogenic, but a
Figure 3. Analysis of the association with myocardial infarction between subjects homozygous for the PlA1 allele and those
homozygous for the PlA2 allele.
doi:10.1371/journal.pone.0101518.g003
The PlA2 Allele and Risk of MI
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complex polygenic interaction with environmental factors [131],
with each additional factor contributing in an additive and
sometimes in a synergistic manner [132]. This contribution can be
clearly demonstrated in the increased risk that smoking adds to
carriage of the PlA2 allele when compared to non-smoking PlA1
homozygotes [82,96,105,123]. It has been suggested that smoking
and PlA2 increase cardiovascular risk via interacting mechanisms
[133], but given the strong association of smoking with premature
myocardial infarction [134], further data are required to test the
strength of this association.
There remains the possibility of unidentified linkage disequilib-
rium with genes modulating other conventional cardiac risk
factors, with elevated plasma lipids being previously linked to
carriage of the PlA2 allele [133]. This hypothesis is however not
supported by the data analysed within the present meta-analysis,
with only one study finding higher triglycerides in carriers of the
PlA2 allele [80] and conflicting reports on the levels of
lipoprotein(a) [86,99]. Interestingly, Grove et al found that the
association between carriage of the PlA2 allele and MI decreased
as cholesterol levels increased, suggesting once again that the true
effect of the PlA2 allele may be diluted and hence concealed by the
concomitant presence of conventional risk factors [96].
The proximity of the PlA1/A2 epitope to the ligand binding site
of GPIIIa has led investigators to consider how the single amino
acid substitution of proline for leucine may affect the cycle of
ligand association and dissociation with the fibrinogen receptor.
Table 2. Subgroup analyses of the association between carriage of the PlA2 allele and myocardial infarction by subject
demographics.
Number of studies
Number of
cases/controls
Pooled OR*
(95% CI)
Association
(p value) I2 (%)
Caucasian 11 5,047/5,538 1.050 0.272 51.9
[71,81,88,95–97,103,109,112,127,128] (0.962–1.146)
Male 11 2,715/5,971 1.145 0.024 39.0
[72,84–86,97,99,114,115,120,123,127] (1.018–1.288)
Female 2 249/4,988 0.961 0.801 0.0
[86,120] (0.703–1.312)
Subgroup analyses based on age of first event:
Age #65 years old{ 23 5,216/10,952 1.101 0.029 57.4
[72,82,84,86,91,97,99,106,107,110,111,114,116,119,121–123,140] (1.010–1.201)
Age #55 years old{ 18 3,744/6,017 1.144 0.007 58.5
[72,82,84,86,91,97,99,106,107,110,111,114,116,119,121–123,140] (1.037–1.261)
Age #45 years old{ 11 3,675/5,872 1.205 0.003 70.3
[72,82,84,86,91,97,107,116,121–123] (1.067–1.360)
First MI1 15 5,011/13,338 1.131 0.006 81.2
[82,84,86,87,90,101,104,107,111,117,119–122,124,125] (1.036–1.234)
*OR (odds ratio) calculated using fixed-effects model for carriage of the PlA2 allele vs PlA1 homozygous subjects.
{Age defined as age of onset of event.
1Event recorded as the first MI experienced by the subject.
[MI = myocardial infarction].
doi:10.1371/journal.pone.0101518.t002
Figure 4. Summary of subgroup analyses based on age at first event. Analysis is of the PlA1/A1 versus PlA1/A2+PlA2/A2 genotype.
doi:10.1371/journal.pone.0101518.g004
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Studies have been inconclusive, with no difference observed in
static systems but an enhancement of binding and outside-in
signalling seen in cell culture under conditions of shear stress, thus
potentially resulting in circulating platelets having a higher basal
level of activation [2]. Similarly to plasma lipids, plasma fibrinogen
concentration has been suggested as a potential modulator of the
increased risk secondary to carriage of the PlA2 allele, but as with
the lipid hypothesis, studies included in this meta-analysis do not
support this association. Three studies reported a higher levels of
fibrinogen in certain subgroups of individuals carrying the PlA2
allele [85,86,121] and two studies reported higher fibrinogen levels
in PlA1 homozygous subjects [124,125].
Resistance to aspirin has been suggested as another potential
mechanism by which carriage of the PlA2 allele may cause
increased cardiovascular risk [135]. However, a recent large meta-
analysis has suggested that this is not the case [136]. There is
however significant inter-study heterogeneity, and the need for
further studies in this regard remains.
A final avenue of investigation has been whether the PlA1/A2
antigens affect the degree or morphology of atherosclerosis.
Carotid plaque morphology was examined by magnetic resonance
imaging in 1,202 participants in the atherosclerotic risk in
communities (ARIC) study [46]. Subjects who carried the PlA2
allele were found to have plaques with thinner fibrous caps, and
these thinner caps represent the major precursor lesion for ACS
[137]. However, this study was limited by a low frequency of the
minor allele and technical constraints resulting in plaque
morphology being assessed only in individuals with thick arterial
walls.
Study limitations
A potential limitation of this meta-analysis is the presence of a
mortality bias that may attenuate or entirely obscure any true
association. Almost a third of individuals with a first major
coronary event die out-of-hospital [138], and are not accounted
for in the predominantly retrospective data presented in this meta-
analysis. In fact, in most studies the subject must have survived a
cardiac event for a number of months or even years to be available
for inclusion. If carriage of the PlA2 allele is more likely to result in
an immediately fatal cardiac event then the association would be
attenuated, with the opposite effect observed if carriage of the
PlA1 allele results in increased early mortality.
The potential presence of a mortality bias can be investigated by
considering post-mortem data from out-of-hospital deaths. The
Helsinki Sudden Death Study considered 700 white Finnish males
(aged 33–70 years old) who had sudden, unexpected out-of-
hospital deaths [139]. Carriage of the PlA2 allele was significant
associated with acute coronary thrombosis in those diagnosed with
sudden cardiac death (OR 3.4; 95% CI 1.5–6.3), with an increased
association observed in those,60 years old (OR 4.6; 95% CI 2.0–
11.2). These results do suggest the presence of a mortality bias, but
the data are not directly comparable to those presented within the
present meta-analysis. Nevertheless, they do indicate that carriage
of the PlA2 has an increased association with platelet-mediated
thrombotic cardiac events, and are therefore consistent with the
increased OR seen for the clinical outcome of MI or indeed ACS.
Figure 5. Analysis of the association between carriage of the PlA2 allele and myocardial infarction based on the use of healthy
controls or controls with known coronary artery disease. Analysis is of the PlA1/A1 versus PlA1/A2+PlA2/A2 genotype.
doi:10.1371/journal.pone.0101518.g005
Table 3. Subgroup analyses of the association of carriage of the PlA2 allele and myocardial infarction by study characteristics.
Number of studies
Number of
cases/controls
Pooled OR*
(95% CI)
Association
(p value) I2 (%)
Subgroup analyses based on control population:
Controls with CAD 17 10,458/19,449 1.024 0.583 19.1
[80,85,87,88,92–94,96,100,105,106,108,114,118,126–128] (0.941–1.114)
Healthy controls 39 4,883/7,016 1.098 0.003 63.3
[70–73,81–84,87–91,96,98,99,101–104,107,108,110,111,113,
115–117,119–124,127,128]
(1.033–1.166)
Subgroup analyses based on study design:
Cohort 17 6,192/12,840 0.996 0.926 0.0
[80,85,86,92–95,97,100,105,106,109,112,114,118,125,126] (0.917–1.082)
Case-control 36 10,671/10,989 1.126 ,0.001 66.7
[70–73,81–84,87–91,96,98,99,101–104,107,108,110,111,113,
115–117,119–124,127,128]
(1.057–1.198)
Subgroup analyses based on number of cases:
,250 cases 37 6,462/3,683 1.240 0.006 59.2
[70,72,73,80–83,85,88–94,97,98,102,103,105,108,110,111,
113–116,118–127,130]
(1.139–1.350)
$250 cases 17 10,401/20,146 0.999 0.864 25.3
[71,72,84,86,87,95,96,99–101,104,106,107,109,112,117,128] (0.935–1.084)
*OR (odds ratio) calculated using fixed-effects model for carriage of the PlA2 allele vs PlA1 homozygous subjects.
[CAD= coronary artery disease].
doi:10.1371/journal.pone.0101518.t003
The PlA2 Allele and Risk of MI
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Figure 6. Analysis of the association between carriage of the PlA2 allele and myocardial infarction based on study design. Analysis is
of the PlA1/A1 versus PlA1/A2+PlA2/A2 genotype.
doi:10.1371/journal.pone.0101518.g006
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Conclusions
In conclusion, carriage of the PlA2 allele is a significant risk
factor for the development of acute coronary events in younger
subjects, with data representing the total population subject to
significant publication bias. This age-skewed risk profile appears to
be the result of the relative impact of the polymorphism becoming
attenuated as conventional cardiovascular risk factors develop with
advancing age. The precise mechanism by which carriage of the
PlA2 allele leads to increased cardiovascular risk remains unclear,
however this should not impair its potential utility in risk
stratification of younger subjects with modifiable risk factors.
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